However, the Majority of Surveyed Urologists Have Not Yet Prescribed Xtandi for
This Patient Population, According to a New Report from BioTrends Research Group
EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that, at 12 months following the U.S. launch of
Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic
castrate-resistant prostate cancer (mCRPC), the majority of surveyed oncologists
stated that they have prescribed Xtandi in clinical practice, whereas the
majority of surveyed urologists indicated that they had not yet prescribed
Xtandi. Of current non-prescribers who plan on prescribing Xtandi for
docetaxel-pretreated mCRPC in the future, the majority of urologists and
oncologists stated that they will prescribe Xtandi within the next six months.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )
The third wave of the LaunchTrends(R) Xtandi (US) report series--fielded 12
months following the launch of Xtandi for docetaxel-pretreated mCRPC in the
United States--finds that surveyed physicians indicated that the lack of steroid
requirement and the efficacy profile of Xtandi are among its top perceived
advantages compared with Johnson & Johnson/Janssen Biotech/Janssen-Cilag's
Zytiga, a finding that is consistent with prior waves of research. Nearly
one-quarter of surveyed physicians indicated that they perceive no disadvantage
of Xtandi compared with Zytiga.
The report also finds that the majority of surveyed physicians stated that
first-line use of Zytiga for the treatment of chemotherapy-naive mCRPC remains
unchanged following the commercial availability of Xtandi in the
docetaxel-pretreated mCRPC setting. According to surveyed oncologists, Zytiga is
currently the first-line patient share leader for the treatment of
chemotherapy-naive mCRPC and will remain so in six months' time.
"Up to half of surveyed physicians indicated that docetaxel-naive asymptomatic
or minimally symptomatic mCRPC and docetaxel-naive symptomatic mCRPC are highly
appropriate patient populations for Xtandi," said Decision Resources Group
Senior Business Insights Analyst Khurram Nawaz, M.Sc. "If Xtandi is approved for
the first-line, asymptomatic or minimally symptomatic mCRPC patient population,
surveyed physicians stated that they would prescribe Xtandi to more than 40
percent of their patients in that setting."
LaunchTrends(R) Xtandi (US) is a three-wave syndicated report series designed to
track the uptake of Xtandi following its launch for docetaxel-pretreated mCRPC
at one month, six months and 12 months following Xtandi's commercial
availability, based upon primary research with U.S. oncologists and urologists.
LaunchTrends assess trial and use of new products, obstacles to use, reasons to
use, typical patient types, line of therapy, product perceptions, promotional
efforts/messages and product satisfaction. For this third wave of research,
BioTrends surveyed 49 U.S. oncologists and 51 U.S. urologists, and conducted
qualitative interviews with 10 U.S. oncologists and urologists in October 2013.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research
to pharmaceutical manufacturers competing in clinically evolving, specialty
pharmaceutical markets. For information on BioTrends publications and research
capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE BioTrends Research Group